Daniel Felix Fleischmann
Overview
Explore the profile of Daniel Felix Fleischmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
93
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bodensohn R, Kaempfel A, Boulesteix A, Orzelek A, Corradini S, Fleischmann D, et al.
Radiother Oncol
. 2023 Jun;
186:109744.
PMID: 37330054
Background And Purpose: There is no randomized evidence comparing whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in the treatment of multiple brain metastases. This prospective nonrandomized controlled single arm trial...
2.
Schnoller L, Piehlmaier D, Weber P, Brix N, Fleischmann D, Nieto A, et al.
Radiat Oncol
. 2023 Mar;
18(1):51.
PMID: 36906590
Despite intensive basic scientific, translational, and clinical efforts in the last decades, glioblastoma remains a devastating disease with a highly dismal prognosis. Apart from the implementation of temozolomide into the...
3.
Fleischmann D, Buttner M, Unterrainer M, Corradini S, Zollner B, Hofmaier J, et al.
Adv Radiat Oncol
. 2023 Mar;
8(3):101185.
PMID: 36896209
Purpose: Translocator protein (TSPO) positron emission tomography (PET) using F-GE-180 shows high tumor-to-brain contrast in high-grade glioma (HGG), even in areas without magnetic resonance imaging (MRI) contrast enhancement. Until now,...
4.
Schnoller L, Albrecht V, Brix N, Nieto A, Fleischmann D, Niyazi M, et al.
Radiat Oncol
. 2022 Apr;
17(1):79.
PMID: 35440003
Background: Inherent resistance to radio/chemotherapy is one of the major reasons for early recurrence, treatment failure, and dismal prognosis of glioblastoma. Thus, the identification of resistance driving regulators as prognostic...
5.
Fleischmann D, Schon R, Corradini S, Bodensohn R, Hadi I, Hofmaier J, et al.
Radiat Oncol
. 2021 Aug;
16(1):165.
PMID: 34454558
Background: Multifocal manifestation of high-grade glioma is a rare disease with very unfavourable prognosis. The pathogenesis of multifocal glioma and pathophysiological differences to unifocal glioma are not fully understood. The...
6.
Bodensohn R, Kaempfel A, Fleischmann D, Hadi I, Hofmaier J, Garny S, et al.
Strahlenther Onkol
. 2021 Apr;
197(7):601-613.
PMID: 33884441
Background: Single-isocenter dynamic conformal arc (SIDCA) therapy is a technically efficient way of delivering stereotactic radiosurgery (SRS) to multiple metastases simultaneously. This study reports on the safety and feasibility of...
7.
Fleischmann D, Jenn J, Corradini S, Ruf V, Herms J, Forbrig R, et al.
Radiother Oncol
. 2019 Jun;
138:99-105.
PMID: 31252301
Purpose: The role of bevacizumab (BEV) in the setting of reirradiation (reRT) of malignant glioma recurrences is poorly defined. At our institution, reRT plus BEV was routinely used until its...
8.
Schnell O, Thorsteinsdottir J, Fleischmann D, Lenski M, Abenhardt W, Giese A, et al.
J Neurooncol
. 2016 Sep;
130(3):591-599.
PMID: 27599828
The place of bevacizumab (BEV) in salvage re-irradiation (Re-RT) settings of malignant glioma is poorly defined. In the current study risk/benefit profiles of two BEV-based Re-RT protocols were analyzed and...